{"id":64598,"date":"2026-05-07T13:21:20","date_gmt":"2026-05-07T05:21:20","guid":{"rendered":"https:\/\/flcube.com\/?p=64598"},"modified":"2026-05-07T13:21:22","modified_gmt":"2026-05-07T05:21:22","slug":"joincare-pharma-secures-nmpa-clinical-trial-approval-for-jkn2501-chinas-first-broad-spectrum-%ce%b2-lactamase-inhibitor-for-drug-resistant-pneumonia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64598","title":{"rendered":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#8217;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia"},"content":{"rendered":"\n<p><strong>Joincare Pharmaceutical Group Industry Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600380:SHA\">SHA: 600380<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical trial approval<\/strong> for <strong>JKN2501<\/strong>, a <strong>Category 1 chemical injection<\/strong> and <strong>novel \u03b2-lactamase inhibitor<\/strong>, to be evaluated in combination with <strong>meropenem<\/strong> for the treatment of <strong>hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP)<\/strong> caused by <strong>Gram-negative or Gram-positive bacteria<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval (Phase not specified)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JKN2501 injection (Category 1 chemical) + meropenem combination<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>7 May 2026<\/td><\/tr><tr><td><strong>Previous Indications<\/strong><\/td><td>Complicated urinary tract infections (cUTI), including acute pyelonephritis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel \u03b2-lactamase inhibitor (chemical injection)<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>\u03b2-lactamases<\/strong> across all major classes (A, B, C, and D), including <strong>class B metallo-\u03b2-lactamases<\/strong> and <strong>OXA-type enzymes<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>World&#8217;s leading and China&#8217;s first broad-spectrum \u03b2-lactamase inhibitor<\/strong> specifically co-designed for use with meropenem<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Does not directly kill bacteria; instead <strong>protects meropenem from hydrolysis<\/strong> by bacterial \u03b2-lactamase enzymes, thereby <strong>restoring meropenem&#8217;s antibacterial activity<\/strong> against drug-resistant strains<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Proprietary design by <strong>Joincare Pharma<\/strong> with global development potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-strategy\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><th>Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>HAP\/VAP<\/strong><\/td><td>Clinical trial approved<\/td><td>Addresses critical need for effective treatments against multidrug-resistant hospital-acquired infections<\/td><\/tr><tr><td><strong>cUTI (including acute pyelonephritis)<\/strong><\/td><td>Previously approved for study<\/td><td>Demonstrates versatility across different infection types requiring broad-spectrum coverage<\/td><\/tr><tr><td><strong>Future Indications<\/strong><\/td><td>Potential expansion<\/td><td>Fixed-dose combination offers high targeting specificity and significant potential for additional indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The dual approach of combining JKN2501 with meropenem represents a strategic response to the growing global threat of <strong>antimicrobial resistance (AMR)<\/strong>, particularly in hospital settings where drug-resistant pathogens pose significant mortality risks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antimicrobial Resistance Crisis:<\/strong> With <strong>AMR causing an estimated 1.27 million deaths globally in 2019<\/strong>, novel approaches to combat drug-resistant infections are urgently needed, particularly in high-burden regions like China.<\/li>\n\n\n\n<li><strong>Hospital Infection Burden:<\/strong> HAP\/VAP represent among the most common and deadly <strong>healthcare-associated infections<\/strong>, with mortality rates reaching <strong>20-50%<\/strong> for infections caused by multidrug-resistant organisms.<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> JKN2501&#8217;s <strong>unprecedented broad-spectrum coverage<\/strong> across all \u03b2-lactamase classes, including the challenging <strong>metallo-\u03b2-lactamases<\/strong>, positions it as a potentially transformative therapy in the antimicrobial arsenal.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> As <strong>China&#8217;s first domestically developed broad-spectrum \u03b2-lactamase inhibitor<\/strong>, JKN2501 aligns with national priorities for pharmaceutical innovation and self-reliance in critical therapeutic areas.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market potential for JKN2501. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics in the antimicrobial space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600380_20260507_36IH.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600380_20260507_36IH.\"><\/object><a id=\"wp-block-file--media-b12937ee-ff49-491e-8b16-a12d9d2366d6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600380_20260507_36IH.pdf\">600380_20260507_36IH<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600380_20260507_36IH.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b12937ee-ff49-491e-8b16-a12d9d2366d6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China&#8217;s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,676,965],"class_list":["post-64598","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-joincare-pharmaceutical","tag-sha-600380"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#039;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP) caused by Gram-negative or Gram-positive bacteria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64598\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#039;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia\" \/>\n<meta property=\"og:description\" content=\"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP) caused by Gram-negative or Gram-positive bacteria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64598\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T05:21:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T05:21:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#8217;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia\",\"datePublished\":\"2026-05-07T05:21:20+00:00\",\"dateModified\":\"2026-05-07T05:21:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Joincare Pharmaceutical\",\"SHA: 600380\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64598#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64598\",\"name\":\"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China's First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-07T05:21:20+00:00\",\"dateModified\":\"2026-05-07T05:21:22+00:00\",\"description\":\"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\\\/VAP) caused by Gram-negative or Gram-positive bacteria.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64598\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64598#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#8217;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China's First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia - Insight, China&#039;s Pharmaceutical Industry","description":"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP) caused by Gram-negative or Gram-positive bacteria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64598","og_locale":"en_US","og_type":"article","og_title":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China's First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia","og_description":"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP) caused by Gram-negative or Gram-positive bacteria.","og_url":"https:\/\/flcube.com\/?p=64598","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-07T05:21:20+00:00","article_modified_time":"2026-05-07T05:21:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64598#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64598"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#8217;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia","datePublished":"2026-05-07T05:21:20+00:00","dateModified":"2026-05-07T05:21:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64598"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Joincare Pharmaceutical","SHA: 600380"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64598#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64598","url":"https:\/\/flcube.com\/?p=64598","name":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China's First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-07T05:21:20+00:00","dateModified":"2026-05-07T05:21:22+00:00","description":"Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for JKN2501, a Category 1 chemical injection and novel \u03b2-lactamase inhibitor, to be evaluated in combination with meropenem for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP\/VAP) caused by Gram-negative or Gram-positive bacteria.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64598#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64598"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64598#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 \u2013 China&#8217;s First Broad-Spectrum \u03b2-Lactamase Inhibitor for Drug-Resistant Pneumonia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64598"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64598\/revisions"}],"predecessor-version":[{"id":64600,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64598\/revisions\/64600"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}